Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19
Status:
Completed
Trial end date:
2021-09-25
Target enrollment:
Participant gender:
Summary
This clinical trial evaluates the safety, efficacy, and biomarker levels of FDA-approved drug
disulfiram in the treatment of adult subjects hospitalized with moderate COVID-19. Disulfiram
may limit the hyperinflammatory response associated with COVID-19 and reduce the risk of
progression to severe illness.
Subjects will be screened and randomized to receive either daily administration of oral
disulfiram or placebo for 14 days. Subjects will be followed up on Day 28.